{
  "docId": "019de075-b7fd-707e-9848-cbfca2408f7c",
  "docSlug": "18b92232553b1610a38c1cd353f6efa7",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 28 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 28,
  "prevPage": 27,
  "nextPage": null,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a split-layout: left side for financial summary, right side for milestones and thesis components.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-b7fd-707e-9848-cbfca2408f7c/28",
  "deckHref": "/decks/019de075-b7fd-707e-9848-cbfca2408f7c",
  "deckJsonHref": "/decks/019de075-b7fd-707e-9848-cbfca2408f7c.json",
  "deckAnchorHref": "/decks/019de075-b7fd-707e-9848-cbfca2408f7c#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.7,
        "y": 0.55
      },
      "kind": "callout",
      "text": "Substantial UPSIDE: LNCs and PS-NPs Facilitating Delivery of Small Molecules and Nucleic Acids; And Establishing Internal and External Pipelines",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "187142a9-9c5c-4d26-b275-824f49c643f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.37,
        "y": 0.55
      },
      "kind": "callout",
      "text": "Solid Value \"FLOOR\" MAT2203: Clinically Validated, Phase 3-ready asset, High unmet need",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9eb3e48c-162b-4077-8814-2b03a2340f42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "Runway into mid Q3 2024; $24.9M in Cash, Cash Equivalents and Marketable Securities; Non-Dilutive Financing Options",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "989e8275-45fc-431b-aada-c25cc4482b3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.6,
        "x": 0.37,
        "y": 0.12
      },
      "kind": "list",
      "text": "Q2 - FDA Meeting and Feedback on MAT2203 Phase 3 IFI program; Q3 - In vitro data from National Resilience Collaboration; Q3 - In vitro data from internal ASO/siRNA program; 2H - Potential MAT2203 Domestic/Global Partnership; 2H - Potential BARDA/ARPA-H Grant; 2H - Potential additional platform collaborations; Q4 - In vivo Data from National Resilience Collaboration; Q4 - In vivo efficacy study data from internal ASO/siRNA program",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58c69886-d560-40c1-bc41-9245b3ef7885",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Matinas Investment Thesis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6578dc4c-923a-4286-8118-d61aef5d7d06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.3,
        "x": 0.37,
        "y": 0.025
      },
      "kind": "title",
      "text": "2023 Milestones & Catalysts",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a57c8065-9827-4687-b667-0d7956293926",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "a62605c8-8fab-4b80-b1a6-15518392a01d",
      "evidence": "The slide presents a clear summary of the company's investment thesis and milestones.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}